Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Analysis of NAT1, NAT2, and ESR1 expression in normal and primary breast tissues and breast cancer cell lines suggested that NAT1 and NAT2 expression are regulated by distinctive mechanisms, whereas NAT1 and ESR1 expression may have overlapping regulation.
|
29901116 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate the relationship between PS and BC by NAT2 variants in Arab-Israeli women, a unique population with low active smoking rates, and high exposure to PS.
|
29071579 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel role for rat NAT2 in mammary cancer was discovered unrelated to carcinogen metabolism, suggesting a role for human NAT1 in breast cancer.
|
28359264 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increasing adherence to the MD reduced BC risk in women with at least one GSTP1 Ile allele (OR for Ile/Ile = 0.84, 95 % CI 0.74-0.95, for Ile/Val = 0.73, 95 % CI 0.62-0.85) or one NAT2 590G allele (OR for 590 GG = 0.73, 95 % CI 0.63-0.83, for 590 GA = 0.81, 95 % CI 0.70-0.94). p interaction values were not, however, statistically significant.
|
26572891 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women.
|
27068825 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results confirm the hypothesis that NAT2 gene polymorphisms (rs1041983 C/T, rs1801280 T/C, and rs1799930 G/A) in association with long-period active smoking could be the possible individual risk-predicting factors for breast cancer development in the population of Slovak women.
|
26700672 |
2016 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although ethnic and geographic differences in NAT2 polymorphisms were present, this was not associated with the risk of breast cancer in general.
|
26796284 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer-specific mortality was significantly increased in smokers with NAT2 slow acetylating status (HR 1.77, 95% CI 1.13-2.79) but not in those with fast acetylating status (HR 1.09, 95% CI 0.60-1.98; Pheterogeneity=0.19).
|
24950597 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was also no interaction between NAT2 acetylator genotype or CYP1A2 polymorphism and HCAs and MDM and red meat intake in relation to breast cancer.
|
24099317 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.
|
23628324 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to verify a possible association between single nucleotide polymomorphisms (SNPs) of NAT2 and the susceptibility to gastric cancer (GC) and breast cancer (BC) in patients from the North region of Brazil.
|
24023296 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three meta-analyses report 35% to 50% increases in breast cancer risk for long-term smokers with N-acetyltransferase 2 gene (NAT2) slow acetylation genotypes.
|
21148114 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common polymorphisms in the N-acetyltransferase 2 gene (NAT2) modify the association between cigarette smoking and bladder cancer and have been hypothesized to determine whether active cigarette smoking increases breast cancer risk.
|
22074863 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among never-active smokers, a long duration of passive smoking was associated with an increased risk of breast cancer (odds ratio (OR) 1.86 (95% confidence interval (95% CI) 1.01-3.44) (test for trend (p=0.07)); that risk was more elevated for NAT2 slow acetylators (OR 2.76, 95% CI 1.16-6.59) (and highest in extremely slow acetylators), but not elevated for NAT2 fast acetylators (OR 1.17, 95% CI 0.42-3.23).
|
20197243 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the NAT2*5 alelle was more statistically correlated with breast cancer patients rather than the controls (p=0.02).
|
20683028 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the modifying role of NAT2 for receptor-defined breast cancer is difficult to interpret in the light of complex mixtures of exposure to AHA.
|
19996973 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, no significantly elevated breast cancer risk was associated with NAT2 slow genotypes when all studies were pooled into the meta-analysis (OR = 1.026, 95% CI = 0.968-1.087).
|
20180012 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44).
|
20180013 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the existence of association between the genetic polymorphisms of metabolizing genes GSTM-1, GSTT-1, and NAT-2, and the presence of mitochondrial genome instability (mtGI) in breast cancer cases.
|
19287511 |
2009 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in N-acetyltransferase2 (NAT2) has been suggested to modify the association of meat intake with breast cancer through its influence on metabolism of HCAs.
|
19116874 |
2009 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Odds ratios (ORs) and 95% confidence intervals (95% CIs) for the joint association of NAT2 with smoking on breast cancer risk were estimated using logistic regression.
|
19692670 |
2009 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Odds ratios (ORs) and 95% confidence intervals (95% CIs) for the joint association of NAT2 with smoking on breast cancer risk were estimated using logistic regression.
|
19692670 |
2009 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively).
|
18423013 |
2008 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results show that cigarette smoking is associated with an increase in breast cancer risk among women with NAT2 slow acetylation genotypes.
|
18187392 |
2008 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CYP1B1 polymorphism may be an important modifier of breast cancer risk in Finnish Caucasian women who have been exposed to tobacco smoke and/or carry the NAT2 slow acetylator genotype.
|
17063266 |
2007 |